The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy

Table 1

Patient characteristics.

Parameters	(%)
Sex
Male	56 (45.2)
Female	68 (54.8)
Age (years)
<60	59 (47.6)
≥60	65 (52.4)
Smoking history
Never smoker	54 (41.5)
Smoker	70 (56.5)
KPS
90-100	55 (44.4)
70-80	69 (55.6)
Histology type
SCC	34 (27.4)
AD	90 (72.6)
Differentiation
Well	21 (16.9)
Moderate	32 (25.8)
Poor	71 (57.3)
Primary site of tumor
Right	66 (53.2)
Left	58 (46.8)
Neurologic symptoms
No	60 (48.4)
Yes	64 (51.6)
Primary T stage
T1	36 (29.0)
T2	41 (33.1)
T3	18 (14.5)
T4	29 (23.4)
Primary N stage
N0	42 (33.9)
N1	45 (36.3)
N2	22 (17.7)
N3	15 (12.1)
Primary AJCC stage
I	87 (70.2)
II	16 (12.9)
III	21 (16.9)
No. of BM
1	74 (59.7)
2	27 (21.8)
3	23 (18.5)
SII
≤480	58 (46.8)
>480	66 (53.2)
NLR
≤2.5	51 (41.1)
>2.5	73 (58.9)
PLR
≤91.5	44 (35.5)
>91.5	80 (64.5)

Abbreviations: KPS: Karnofsky performance status; SCC: squamous cell carcinoma; AD: adenocarcinoma; BM: brain metastasis; SII: systemic immune-inflammation index; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio.